Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network

<b>Background:</b> The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. <b...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Concetta Conticello, Alessandra Romano, Vittorio Del Fabro, Enrica Antonia Martino, Valeria Calafiore, Giuseppe Sapienza, Valerio Leotta, Marina Silvia Parisi, Uros Markovic, Bruno Garibaldi, Salvatore Leotta, Emilia Cotzia, Vanessa Innao, Donato Mannina, Santo Neri, Maurizio Musso, Renato Scalone, Clotilde Cangialosi, Francesco Acquaviva, Giovanni Cardinale, Anxur Merenda, Cinzia Maugeri, Giuseppina Uccello, Massimo Poidomani, Giuseppe Longo, Melania Carlisi, Daniele Tibullo, Francesco Di Raimondo
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI AG 2019-06-01
Серии:Journal of Clinical Medicine
Предметы:
KRd regimen
multiple myeloma
salvage therapy
Online-ссылка:https://www.mdpi.com/2077-0383/8/6/877
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы